Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
OX2 Therapeutics
AddedFeb 18, 2024
UpdatedJun 18, 2026
OX2 Therapeutics

OX2 Therapeutics

OX2 Therapeutics: Innovating brain tumor treatments via immune system activation.

HQ
Lakeville, MN, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

OX2 Therapeutics, founded with a mission to revolutionize brain tumor treatment, focuses on developing innovative therapies that activate the immune system to combat cancer. Their flagship product is a novel CD200 Checkpoint peptide inhibitor, which enables the immune system to penetrate blood vessel walls and target cancer cells effectively. The company aims to provide healthcare institutions with advanced tools to treat central nervous system tumors and potentially other solid tumors.

Notable achievements include receiving FDA approval for a Phase I clinical trial to treat high-grade glioblastoma with their peptide checkpoint inhibitor, CD200AR-L. This milestone underscores their commitment to pioneering new cancer treatments. OX2 Therapeutics' work has the potential to significantly impact the field of oncology by offering new hope for patients with aggressive brain tumors and possibly other cancers.

OX2 Therapeutics - Similar Companies

Oxeia Biopharmaceuticals logo

Oxeia Biopharmaceuticals

oxeiabiopharma.com

Pheast Therapeutics logo

Pheast Therapeutics

pheast.com

OncoSpherix logo

OncoSpherix

oncospherix.com

BioEclipse Therapeutics logo

BioEclipse Therapeutics

bioeclipse.com

OS Therapies logo

OS Therapies

ostherapies.com

Oxalo Therapeutics logo

Oxalo Therapeutics

Ostentus Therapeutics logo

Ostentus Therapeutics

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

Checkpoint Therapeutics logo

Checkpoint Therapeutics

checkpointtx.com

Ocelot Bio logo

Ocelot Bio

ocelotbio.com

OncoMyx Therapeutics logo

OncoMyx Therapeutics

oncomyx.com

AsclepiX Therapeutics logo

AsclepiX Therapeutics

asclepix.com

A2 Biotherapeutics logo

A2 Biotherapeutics

a2bio.com

Xios Therapeutics logo

Xios Therapeutics

Neonc Technologies logo

Neonc Technologies

neonctech.com

OX2 Therapeutics - Quick Facts

Who are OX2 Therapeutics' competitors?

Companies similar to OX2 Therapeutics include Oxeia Biopharmaceuticals, Pheast Therapeutics, OncoSpherix and BioEclipse Therapeutics.

When was OX2 Therapeutics founded?

OX2 Therapeutics was founded in 2016.

Where is OX2 Therapeutics' headquarters located?

OX2 Therapeutics' headquarters is located in Lakeville, MN, US.

When was OX2 Therapeutics' last funding round?

OX2 Therapeutics' most recent funding round was for $649.4k (USD) in September 2020.

How much has OX2 Therapeutics raised to-date?

As of Sep 21, 2020, OX2 Therapeutics has raised a total of $649.4k (USD).

How many employees does OX2 Therapeutics have?

OX2 Therapeutics has 7 employees as of Feb 5, 2024.

OX2 Therapeutics - Classification

Industry
  • Therapeutics
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Treatment
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified